Related Experiment Videos
Salvage radiotherapy following radical prostatectomy
Charles Catton1, Michael Milosevic
1Department of Radiation Oncology, Princess Margaret Hospital and University of Toronto, 610 University Avenue, M5G 2M9, Toronto, Canada. charles.catton@rmp.uhn.on.ca
World Journal of Urology
|August 19, 2003
Summary
Salvage radiotherapy after prostatectomy can cure many men with biochemical relapse. Early treatment offers better outcomes, and patients should be considered for clinical trials to optimize selection and timing.
Area of Science:
- Oncology
- Radiation Oncology
- Urology
Background:
- Biochemical relapse after radical prostatectomy affects 17-64% of men.
- Prostate cancer progression to metastatic disease and death can occur in up to one-third of men with relapse.
Purpose of the Study:
- To evaluate the role of postoperative salvage radiotherapy (RT) for men with biochemical relapse after prostatectomy.
- To identify prognostic factors influencing response to salvage RT.
- To highlight the need for prospective data to optimize patient selection and treatment timing.
Main Methods:
- Review of existing data on salvage radiotherapy outcomes.
- Analysis of prognostic factors including Gleason score, PSA doubling time, time to PSA re-emergence, surgical margins, anastomotic biopsy, and PSA level.
- Discussion of the potential benefits of early treatment and sensitive PSA assays.
Main Results:
- Salvage RT is well-tolerated and potentially curative for biochemical relapse.
- Favorable prognostic factors (Gleason <8, PSA doubling time >10 months, PSA >2 years) predict lower metastatic risk but do not exclude others from treatment.
- PSA level at RT initiation is a strong indicator of durable response; earlier treatment is likely more effective.
Conclusions:
- Salvage RT should be considered for all men with biochemical relapse post-prostatectomy.
- Patient selection should not solely rely on prognostic factors; early treatment is encouraged.
- Prospective randomized trials are needed to refine patient selection, optimal treatment timing, and the role of adjuvant hormone therapy.